A Prescription Drug User Fee Act target date of June 20, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Findings showed 20% of patients treated with dupilumab experienced sustained disease remission at week 36 compared with 4% of those who received placebo. Treatment with dupilumab led to significant ...

Bullous pemphigoid is a potentially debilitating autoimmune bullous disease presenting with urticarial plaques, subepidermal bullae, erosions, and pruritus, classically in elderly individuals. This ...

Please provide your email address to receive an email when new articles are posted on . Nomacopan was well tolerated and beneficial in patients with bullous pemphigoid, according to phase 2a clinical ...

Bullous pemphigoid (BP) is a condition that affects the skin with an autoimmune etiology. It is often seen in those over the age of 80 and the prevalence is even higher in elderly people with ...

Use of certain dipeptidyl peptidase 4 (DPP-4) inhibitors appears to be associated with a small but significantly elevated risk for developing the chronic blistering skin condition bullous pemphigoid, ...

An 86-year-old man with a 7-month history of widespread pruritic bullae was referred to our dermatology clinic by his family physician. Physical examination showed tense bullae on his trunk and ...

Please provide your email address to receive an email when new articles are posted on . Sustained disease remission occurred in 20% of the study cohort vs. 4% of the placebo group at week 36. 41% of ...

The UK's vaccination record is world-beating, with more than three quarters of the population now fully vaccinated. The booster campaign has been key to neutralising the threat posed by the new ...

Bullous pemphigoid is an autoimmune disease that causes painful chronic blisters and welts. The condition is rare, and typically affects older adults. Sufferers' average age is 80 and usually already ...